Electronic physician · 2017
Effect of metformin on the anti-Müllerian hormone level in infertile women with polycystic ovarian syndrome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Foroozanfard Fatemeh, Samimi Mansooreh, Almadani Kosar Hosseini, Sehat Mojtaba
Аннотация
BACKGROUND: Polycystic ovary syndrome (PCOS) is the major cause of anovulatory infertility in women. The level of serum Anti-Mullerian Hormone (AMH) in patients can be 2-3 times higher than in healthy women. The aim of this study was to assess the effect of metformin on AMH level in PCOS patients suffering from infertility.
METHODS: In this pre and post clinical trial, 30 infertile patients with PCOS were enrolled according to the Rotterdam criteria. The serum AMH level was recorded before and after 8 weeks of treatment with metformin (1500 mg daily). We used SPSS version 17 and paired samples t-test, multiple linear regression and ANCOVA test for data analysis.
RESULTS: Serum AMH level was significantly decreased after 8 weeks of treatment with metformin [10±3.75 (ng/ml) versus 7.8±3.7 (ng/ml)] (p=0.008, 95% CI: 0.60-3.75). Also, AMH level change was directly associated to BMI in PCOS patients. In other words, in these patients, a higher BMI led to more decrease in AMH level after metformin treatment.
CONCLUSION: Eight weeks' treatment with metformin would significantly decrease AMH. AMH level change was directly associated to BMI.
CLINICAL TRIAL REGISTRATION: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: 201403132967N5.
FUNDING: This study was funded by the Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences (Grant Number: 9322).
METHODS: In this pre and post clinical trial, 30 infertile patients with PCOS were enrolled according to the Rotterdam criteria. The serum AMH level was recorded before and after 8 weeks of treatment with metformin (1500 mg daily). We used SPSS version 17 and paired samples t-test, multiple linear regression and ANCOVA test for data analysis.
RESULTS: Serum AMH level was significantly decreased after 8 weeks of treatment with metformin [10±3.75 (ng/ml) versus 7.8±3.7 (ng/ml)] (p=0.008, 95% CI: 0.60-3.75). Also, AMH level change was directly associated to BMI in PCOS patients. In other words, in these patients, a higher BMI led to more decrease in AMH level after metformin treatment.
CONCLUSION: Eight weeks' treatment with metformin would significantly decrease AMH. AMH level change was directly associated to BMI.
CLINICAL TRIAL REGISTRATION: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: 201403132967N5.
FUNDING: This study was funded by the Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences (Grant Number: 9322).